Perspective

Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019

Disclosures: Dr Holsworth has no conflicts of interest to report. Dr Rajasekaran reports to have unrelated National Institute of General Medicine Sciences–funded parent R01 (1R01GM134307-01) on pediatric multiorgan dysfunction. Dr Hartog reports to have served on the advisory boards of Genentech, Horizon Pharmaceuticals, Orchard Therapeutics, and Pharming Healthcare and in the speakers bureau of Horizon Pharmaceuticals and Takeda that are all unrelated to the current topic.

Funding: The authors have no funding sources to report.